Donate For Public and Patients Store Search

F061 - Late-breaking Research: Clinical Trials

Saturday, February 17; 1:00 PM - 3:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Describe ground-breaking scientific developments in dermatologic research.
  • Evaluate and apply information from recent investigations to clinical practice.

Description

These forums will highlight the latest ground-breaking observations in clinical, therapeutics, surgical, pediatric, dermatopathologic and basic research. Researchers are invited to submit abstracts describing their most recent results and the top scoring studies will be invited to discuss their findings in a brief oral presentation during one of the themed Forums.

Disclosures

  • Baum, Sharon A., MD: Immune Pharmaceuticals – I(Grants/Research Funding);
  • Bissonnette, Robert, MD, MSc: AbbVie – I(Grants/Research Funding); Bausch Health – C(H); BMS – A(H), I(Grants/Research Funding); Boehringer Ingelheim – A(H), I(Grants/Research Funding); Boston Pharmaceuticals – C(H); Dermavant Sciences – C(H), I(Grants/Research Funding); Eli Lilly and Company – A(H), I(Grants/Research Funding); Escalier – I(Grants/Research Funding); Janssen-Ortho Inc. – C(H), I(Grants/Research Funding); Pfizer Inc. – A(H), I(Grants/Research Funding); Sienna Biopharmaceuticals – C(H), I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(H), I(Grants/Research Funding);
  • Blauvelt, Andrew, MD: AbbVie – A(H), C(H), I(Fees), SP(H); Aclaris Therapeutics Inc. – A(H), C(H), I(Fees); Akros Pharma, Inc. – A(H), C(H); Allergan, Inc – A(H), C(H), I(Fees); Almirall – A(H), C(H); Amgen – A(H), C(H), I(Fees); Arena Pharmaceuticals – A(H), C(H); Athenex – A(H), C(H), I(Fees); Boehringer Ingelheim – A(H), C(H), I(Fees); Bristol-Myers Squibb – A(H), C(H); Celgene – A(H), C(H), I(Fees); Dermavant Sciences – A(H), C(H), I(Fees); Dermira – A(H), C(H), I(Fees); Eli Lilly and Company – A(H), C(H), I(Fees); FLX Bio – A(H), C(H); Forte Biosciences – A(H), C(H); Galderma Laboratories, L.P. – A(H), C(H); Galderma USA – I(Fees); Genentech, Inc. – A(H), C(H), I(Fees); GlaxoSmithKline – A(H), C(H), I(Fees); Janssen-Ortho Inc. – A(H), C(H), I(Fees), SP(H); Leo Pharma Inc – A(H), C(H), I(Fees); Meiji Seika Pharma Co., Ltd – A(H), C(H); Merck & Co., Inc – A(H), C(H), I(Fees); Novartis Pharmaceuticals Corp. – A(H), C(H), I(Fees); Pfizer Inc. – A(H), C(H), I(Fees); Purdue Pharma – A(H), C(H); Regeneron – A(H), C(H), I(Fees), SP(H); Revance Therapeutics, Inc. – I(Fees); Sandoz, a Novartis company – A(H), C(H), I(Fees); Sanofi – A(H), C(H), SP(H); Sienna Biopharmaceuticals – A(H), C(H), I(Fees); Sun Pharmaceutical Industries Ltd. – A(H), C(H); UCB – A(H), C(H), I(Fees); Valeant Pharmaceuticals International – A(H), C(H), I(Fees); Vidac Pharma – A(H), C(H), I(Fees);
  • Gelfand, Joel M., MD, MSCE: AbbVie – I(Grants/Research Funding); BMS – C(Fees); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Eli Lilly and Company – O(Fees); GlaxoSmithKline – C(H); Janssen Pharmaceuticals, Inc – C(H), I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Ortho Dermatologics – I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Sanofi US Services – C(H); Society for Investigative Dermatology – O(H); UCB – O(Fees);
  • Giamarellos-Bourboulis, Evangelos J., MD, PhD: AbbVie – A(H), I(Grants/Research Funding); InflaRx GmbH – C(H), I(Grants/Research Funding); XBiotech – C(H), I(Grants/Research Funding);
  • Gordon, Kenneth B., MD: AbbVie – C(H), I(Grants/Research Funding); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Celgene Corporation – A(H), I(Grants/Research Funding); Demira – C(H); Dermavant Sciences – C(H); Eli Lilly and Company – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – C(H); Leo Pharma Inc – C(H); Lilly ICOS LLC – A(H); Novartis – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H); Othro Dermatologics – C(H); Pfizer Inc. – A(H); Sun Pharmaceutical Industries Ltd. – C(H); UCB – C(H);
  • Guttman, Emma, MD, PhD: AbbVie – C(H), I(Grants/Research Funding); Almirall – A(H), C(H), I(Grants/Research Funding); Amgen – C(H), I(Grants/Research Funding); AnaptysBio – I(Grants/Research Funding); Asana Biosciences, LLC – A(H), C(H), I(Grants/Research Funding); Boehringer Ingelheim – A(H), C(H), I(Grants/Research Funding); Cara Therapeutics – A(H), C(H); Celgene Corporation – A(H), C(H), I(Grants/Research Funding); Concert Pharmaceuticals – C(H), I(Grants/Research Funding); DBV Technologies – A(H), C(H); Dermavant Sciences – A(H), I(Grants/Research Funding); Dermira – A(H), C(H), I(Grants/Research Funding); DS Biopharma – C(H), I(Grants/Research Funding); Eli Lilly and Company – A(H), C(H), I(Grants/Research Funding); EMD Serono – C(H); Escalier – A(H), C(H); FLX Bio – C(H); Galderma Research & Development, LLC – A(H), C(H), I(Grants/Research Funding); Glenmark Generics Inc. – A(H), C(H), I(Grants/Research Funding); Incyte Corporation – A(H); Innovaderm Research Inc. – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – A(H), C(H), I(Grants/Research Funding); Leo Pharma Inc – A(H), C(H), I(Grants/Research Funding); Mitsibushi Pharma – C(H); Novan – A(H), I(Grants/Research Funding); Novartis – A(H), C(H), I(Grants/Research Funding); Pfizer Inc. – A(H), C(H), I(Grants/Research Funding); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Regeneron – A(H), C(H); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Funding); Sanofi – A(H), C(H); Sienna Biopharmaceuticals – A(H), C(H), I(Grants/Research Funding); UCB – I(Grants/Research Funding); Union Therapeutics – C(H), I(Grants/Research Funding);
  • Ogg, Graham, MD, PhD: AnaptysBio – I(Grants/Research Funding), O(OB); Celgene – I(Grants/Research Funding); Grunenthal – C(Fees); Novartis – I(Grants/Research Funding); Orbit Discovery – B(ST); Regeneron – I(Grants/Research Funding); UCB – C(OB);
  • Papp, Kim A., MD: AbbVie – A(H), C(H), I(Grants/Research Funding), O(H), SP(H); Akros Pharma, Inc. – C(H), I(Grants/Research Funding), O(H); Amgen – A(H), C(H), I(Grants/Research Funding), O(H), SP(H); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding), O(Grants/Research Funding); Arcutis, Inc. – C(Grants/Research Funding), I(Grants/Research Funding); Astellas Pharma Canada, Inc. – A(Grants/Research Funding), C(Grants/Research Funding), I(Grants/Research Funding), SP(Grants/Research Funding); Bausch Health – A(H), C(H), I(Grants/Research Funding), O(H), SP(H); Baxalta Incorporated – C(Grants/Research Funding); Boehringer Ingelheim – A(H), C(H), I(Grants/Research Funding), O(H); Bristol-Myers Squibb – A(Grants/Research Funding), C(Grants/Research Funding); Can-Fite BioPharma, Ltd. – C(Grants/Research Funding), I(Grants/Research Funding); Celgene Corporation – A(H), C(H), I(Grants/Research Funding), O(H), SP(H); Coherus Biosciences – C(H), I(Grants/Research Funding); Dermira – C(Grants/Research Funding), I(Grants/Research Funding); Dow Pharmaceutical Sciences, Inc. – C(Grants/Research Funding), I(Grants/Research Funding); Eli Lilly and Company – A(H), C(H), I(Grants/Research Funding), O(H), SP(H); Galderma Canada, Inc – A(H), C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – C(Grants/Research Funding), I(Grants/Research Funding); Gilead Sciences – I(Grants/Research Funding); GlaxoSmithKline – I(Grants/Research Funding); InflaRx – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), C(H), I(Grants/Research Funding), O(H), SP(H); Kyowa Hakko Kirin Pharma, Inc. – C(H), I(Grants/Research Funding), O(H), SP(H); Leo Pharma Inc – C(Grants/Research Funding), I(Grants/Research Funding), SP(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Meiji Seika Pharma Co., Ltd – C(NC); Merck – A(H), C(H), I(Grants/Research Funding), O(H), SP(H); Merck Serono – C(H), I(Grants/Research Funding), O(H); Mitsibushi Pharma – C(H); Moberg Pharma North America LLC – I(Grants/Research Funding); Novartis – A(H), C(H), I(Grants/Research Funding), O(H), SP(H); Pfizer Inc. – A(H), C(H), I(Grants/Research Funding), O(H), SP(H); PRCL Research – C(H), I(Grants/Research Funding); Regeneron – A(Grants/Research Funding), C(Grants/Research Funding), I(Grants/Research Funding), O(Grants/Research Funding); Roche Laboratories – C(Grants/Research Funding), I(Grants/Research Funding); Sanofi – A(H), C(H), I(Grants/Research Funding), O(H), SP(H); Sun Pharmaceutical Industries Ltd. – A(Grants/Research Funding), I(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – C(H), I(Grants/Research Funding); UCB – A(H), C(H), I(Grants/Research Funding);
  • Reich, Kristian D.J., MD, PhD: A(H), O(H), SP(H); Affibody – A(H); Almirall – A(H); Amgen – A(H); Biogen – A(H), SP(H); Boehringer Ingelheim – A(H); Celgene – A(H); Celgene Corporation – SP(H); Centocor Ortho Biotech Inc. – A(H); Covegan – SP(H); Eli Lilly and Company – SP(H); Forward Pharma – C(H); Fresenius Medical Care – A(H); GlaxoSmithKline – SP(H); Janssen-Cilag – SP(H); Kyowa Hakko Kirin Pharma, Inc. – A(H); Leo Pharma A/S – SP(H); Lilly ICOS LLC – A(H); Medac Pharma, Inc – SP(H); Merck & Co., Inc. – SP(H); Miltenyi Biotec Inc. – A(H); Novartis Pharmaceuticals Corp. – A(H); Pfizer Inc. – Data Safety Monitoring Board(H); Regeneron – A(H); Samsung – A(H); Sanofi – A(H); Takeda Pharmaceuticals USA Inc – A(H); UCB – A(H); Valeant Pharmaceuticals International – A(H); Xenoport, Inc. – A(H);
  • Silverberg, Jonathan I., MD, PhD, MPH: AbbVie – C(H), I(NC); AnaptysBio – C(H); Asana Biosciences, LLC – C(H); Dermira – A(H); Eli Lilly and Company – C(H), I(NC); Galderma Research & Development, LLC – C(H); GlaxoSmithKline – C(H), I(NC); Glenmark Generics Inc. – C(H); Kiniksa Pharmaceuticals, Ltd. – C(H), I(NC); Leo Pharma Inc – A(H); Leo Pharma Inc. – I(H); Medimmune – C(H); Menlo Therapeutics – A(H), I(NC); Pfizer Inc. – A(H), C(H); Regeneron – C(H), I(NC), SP(H); Sanofi – C(Grants/Research Funding);
  • Thaci, Diamant: AbbVie – A(H), I(Fees), Speaker/Faculty Education(H); Almirall – A(H), Speaker/Faculty Education(H); Beiersdorf, Inc. – C(H); Boehringer Ingelheim – A(H); Celgene – A(H), I(Fees), I(Grants/Research Funding), SP(H); Eli Lilly and Company – A(H), I(Fees), SP(H); Galapagos NV – Data Safety Monitoring Board(H); GlaxoSmithKline – I(Fees); Hexal AG, Sandoz Biopharmaceuticals – A(H), SP(H); Janssen-Cilag – A(H), C(H), I(Fees), SP(H); Leo Pharma Inc – A(H), I(Fees); Medac Pharma, Inc – SP(H); Novartis Pharmaceuticals Corp. – A(H), I(Fees), I(Grants/Research Funding), Speaker/Faculty Education(H); Parexel – I(Fees); Pfizer Inc. – A(H), I(Fees), Speaker/Faculty Education(H); Regeneron – I(Fees), Speaker/Faculty Education(H); Sanofi – A(H), Speaker/Faculty Education(H); Schering-Plough Corporation – SP(H); UCB – A(H), I(Fees), Speaker/Faculty Education(H);
  • Tsao, Hensin, MD, PhD: Asana Biosciences, LLC – I(Grants/Research Funding); Epiphany Dermatology – A(H); Massachusetts General Hospital – E(S); Relay Therapeutics – I(Grants/Research Funding); UpToDate, Inc. – O(H); Worldcare Clinical, LLC – C(H);
  • Yazici, Yusuf: no financial relationships exist with commercial interests.
Schedule
Saturday, February 17
1:00 PM
Dr. Guttman / Primary Results from a Phase 2b, Randomized, Placebo-Controlled Trial of Upadacitinib for Patients with Atopic Dermatitis
1:10 PM
Dr. Bissonnette / Efficacy and Safety of Oral ASN002, a Novel JAK/SYK inhibitor, in Patients with Moderate-to-Severe Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Clinical Study.
1:20 PM
Dr. Silverberg / Patient-reported Outcomes (PROs) from a Phase 2 Double-blinded, Randomized, Multi-center, Placebo-controlled Study of Baricitinib in Adult Patients with Moderate-to-severe Atopic Dermatitis (AD)
1:30 PM
Dr. Thaci / MOR106, an Anti-IL-17C mAb, a Potential New Approach for Treatment of Moderate-to-severe Atopic Dermatitis: Phase 1 Study.
1:40 PM
Ogg / Proof-of-concept Phase 2a Clinical Trial of ANB020 (anti-IL-33) in the Treatment of Moderate-to-severe Atopic Dermatitis
1:50 PM
Dr. Gordon / Efficacy and Safety of Risankizumab: Results from Two Double-blind, Placebo- and Ustekinumab-controlled, Phase 3 Trials in Moderate-to-severe Plaque Psoriasis
2:00 PM
Dr. Reich / Long-term Efficacy of Guselkumab Treatment After Drug Withdrawal and Retreatment in Patients with Moderate-severe Plaque Psoriasis: Results from VOYAGE 2
2:10 PM
Dr. Papp / Dual Neutralization of Interleukin (IL)-17A and IL-17F with Bimekizumab in Moderate-to-severe Psoriasis: Results from a Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study
2:20 PM
Dr. Gelfand / A Phase Iv, Randomized, Double-blind, Placebo-controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (The Vip-U Trial)
2:30 PM
Yazici / Apremilast for Behçet’s Syndrome: A Phase III Randomized, Placebo-controlled, Double-blind Study
2:40 PM
Giamarellos-Bourboulis / Efficacy of IFX-1, an Anti-C5a Monoclonal Antibody, in an Open Label Phase 2a Study in Patients with Hidradenitis Suppurativa not Eligible for Adalimumab
2:50 PM
Dr. Baum / A Pilot Phase 2a Study of the Safety and Efficacy of Bertilimumab, an Anti-eotaxin-1 Antibody, in Bullous Pemphigoid
Event Details
  • Date
    Saturday, February 17
  • Time
    1:00 PM - 3:00 PM
  • Location
    Ballroom 20A
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
Speakers
  • Andrew Blauvelt, MD, FAAD
  • Diamant Thaci
  • Emma Guttman, MD, PhD, FAAD
  • Evangelos J. Giamarellos-Bourboulis, MD, PhD - Handout
  • Graham Ogg, MD, PhD
  • Joel M. Gelfand, MD, MSCE, FAAD
  • Jonathan I. Silverberg, MD, PhD, MPH, FAAD
  • Kenneth B. Gordon, MD, FAAD
  • Kim A. Papp, MD, FAAD
  • Kristian D.J. Reich, MD, PhD
  • Robert Bissonnette, MD, MSc, FAAD
  • Sharon A. Baum, MD
  • Yusuf Yazici